· Education · Education Desk
Luxury lifestyle coverage, physician-led clinics, and a new nationwide telehealth launch are repositioning tesamorelin and physician-supervised peptide therapy from biohacker fringe to mainstream care.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.